APO-VERAP TAB 80MG TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

VERAPAMIL HYDROCHLORIDE

Saadav alates:

APOTEX INC

ATC kood:

C08DA01

INN (Rahvusvaheline Nimetus):

VERAPAMIL

Annus:

80MG

Ravimvorm:

TABLET

Koostis:

VERAPAMIL HYDROCHLORIDE 80MG

Manustamisviis:

ORAL

Ühikuid pakis:

100/500

Retsepti tüüp:

Prescription

Terapeutiline ala:

MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0113846002; AHFS:

Volitamisolek:

MARKETED

Loa andmise kuupäev:

1989-12-31

Toote omadused

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
APO-VERAP
Verapamil Hydrochloride
Tablets, 80 mg and 120 mg, oral
BP
Antianginal / Antiarrhythmic / Antihypertensive Agent
APOTEX INC.
150 Signet Drive,
Weston, Ontario
M9L 1T9.
Date of Initial Authorization:
JUN 30, 1989
Date of Revision:
MAY 12, 2022
www.apotex.ca/products
Submission Control Number: 258995
_ _
_VERAPAMIL HYDROCHLORIDE TABLETS (verapamil hydrochloride) _
_Page 2 of 48_
RECENT MAJOR LABEL CHANGES
1 Indications, 1.1 Pediatrics
05/2022
1 Indications, 1.2 Geriatrics
05/2022
2 Contraindications
05/2022
4 Dosage and Administration, 4.2 Recommended Dose and
Dosage Adjustment
05/2022
7 Warnings and Precautions, Cardiovascular
05/2022
7 Warnings and Precautions, Hepatic/Biliary/Pancreatic
05/2022
7 Warnings and Precautions, Monitoring and Laboratory tests
05/2022
7 Warnings and Precautions, Neurologic
05/2022
7 Warnings and Precautions, 7.1.1 Pregnant Women
05/2022
7 Warnings and Precautions, 7.1.3 Pediatrics
05/2022
TABLE OF CONTENTS
Sections or subsections that are not applicable at the time of
authorization are not listed.
RECENT MAJOR LABEL
CHANGES..............................................................................................2
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................5
1
INDICATIONS
................................................................................................................5
1.1
Pediatrics
............................................................................................................5
1.2
Geriatrics.............................................................................................................5
2
CONTRAINDICATIONS
...................................................................................................5
4
DOSAGE AND
ADMINISTRATION..........................................